RedHill Biopharma Ltd (RedHill) is a specialty biopharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal (GI) and infectious diseases. The company’s current commercial portfolio includes two FDA-approved products addressing important unmet needs in GI-related infections. Talicia is an all-in-one oral capsule that combines omeprazole, amoxicillin, and rifabutin for the treatment of Helicobacter pylori infection in adults, offering a simplified regimen designed to improve eradication outcomes. Aemcolo (rifamycin) is an oral antibacterial indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

RedHill is actively engaged in the research and development of therapeutic candidates, focusing on advancing clinical and non-clinical trials. The company is prioritizing the development of its pipeline, which includes candidates such as Opaganib, RHB-204, RHB-107, and RHB-102. The company is also involved in commercialization and out-licensing efforts for its therapeutic candidates and in-licensed or acquired products. The R&D activities are supported by grants and industry partners, and the company is committed to advancing its therapeutic candidates through the regulatory approval process. The company’s R&D unit is responsible for managing the company's research and development activities, which include conducting clinical trials, manufacturing therapeutic candidates, and providing regulatory services. The unit oversees the development of the company's therapeutic pipeline and ensures compliance with regulatory standards such as good clinical practices (GCP). In FY2025, the company invested US$2 million in its research and development activities.